Identification of biomarkers predictive of dasatinib effects in cancer cells

摘要: A method of predicting response to treatment with inhibitors EGFR and SRC by screening for status key biomarkers such as EGFR. Dasatinib is a drug that can inhibit group proteins called proteins. In addition, other experiments have suggested important signaling are affected dasatinib. Early phase trials dasatinib ongoing in cancer patients. It will be determine which patients receive clinical benefit Predetermination performed assessing tumors prior or SRC. Patients positive could then treated higher confidence while those not possessing these predictive would avoid ineffective potentially toxic therapy. Additionally, tailored according predetermined sensitivity evaluating indicated correlating one more agents.